-- 
Ampal, Elbit Imaging, Modiin and Teva: Israeli Equity Preview

-- B y   S h a r o n   W r o b e l
-- 
2011-07-12T06:39:24Z

-- http://www.bloomberg.com/news/2011-07-12/ampal-elbit-imaging-modiin-and-teva-israeli-equity-preview.html
The following stocks may rise or
fall in Israeli markets. Stock symbols are in parentheses after
the company names and prices are from the last close unless
otherwise stated.  The TA-25 Index lost 1.7 percent to 1,247.38 in Tel Aviv.  Ampal-American Israel (AMPL)  Corp: Militants blew up an
Egyptian pipeline terminal that supplies gas to  Israel  in a pre-
dawn attack, the state-run Middle East News Agency reported
today. The owner of a 12.5 percent stake in East Mediterranean
Gas Co., which supplies the gas, fell 0.2 percent to 3.098
shekels.  Oil Refineries Ltd. (ORL)  , which has agreements to
buy gas from EMG, dropped 2.8 percent to 2.391 shekels.  Elbit Imaging Ltd. (EMIT)  : The Gamida Cell-Teva Joint
Venture said the data monitoring committee has recommended the
venture continue to enroll patients for a Phase III study of
StemEx, a cord blood stem cell product, for leukemia and
lymphoma. Elbit, which owns about 32 percent of Gamida,
retreated 2.4 percent to 22.04 shekels.  Clal Biotechnology
Industries Ltd. (CBI)  , which also has a stake in Gamida, lost
1.9 percent to 19.41 shekels.  Modiin LP (MDINL IT): The oil and gas exploration company
and its partners in the Sara and Myra licenses asked Israel’s
regulator for a two-month delay to Feb. 28, 2012 for the start
of the first drill at the sites. Modiin slid 4.4 percent to
0.044 shekel.  Teva Pharmaceutical Industries Ltd. (TEVA)  :  Roche
Holding AG  filed a lawsuit seeking to block generic-drug
companies including Novartis AG’s Sandoz and Teva, the world’s
largest maker of generic pharmaceuticals, from selling a low-
cost version of the anti-nausea drug Aloxi. Teva declined 0.9
percent to 167.50 shekels.  To contact the reporter on this story:
Sharon Wrobel in  Tel Aviv  at 
 swrobel4@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  